米国市場銘柄情報

SABS SABバイオセラピューティクス

銘柄追加

4.0200
-0.0800-1.95%

終値 05/02 16:00 ET

3,708.65万時価総額-526直近PER

SABバイオセラピューティクスに関するコメント

ログインコメントを投稿

Stock_Drift

04/17 08:57

4/17/24 Watchlist 📊⚡️📊⚡️📊⚡️📊
$ビヨンド・カンナソフト・エンタープライゼス(BCAN.US)$$SABバイオセラピューティクス(SABS.US)$$マカタワ・バンク(MCBC.US)$$ドラゴンフライ・エナジー・ホールディングス(DFLI.US)$$マイサイズ(MYSZ.US)$$サウンドハウンド・エーアイ(SOUN.US)$$ARK 21Shares Bitcoin ETF(ARKB.US)$
📊⚡️📊 #stock_drift24
⭐️just a watchlist, not financisl advice⭐️

Trytosaveabit

04/16 19:24

Trial update

$SABバイオセラピューティクス(SABS.US)$ SAB Biotherapeutics' Has Completed Dosing The Third Cohort For Phase 1 Study Of SAB-142 In Healthy Volunteers And Participants With Type 1 Diabetes With No Observation Of Serum Sickness Thus Far

Jaguar8

04/16 19:17

$SABバイオセラピューティクス(SABS.US)$
NEWS
SAB Biotherapeutics Provides SAB-142 Trial Update
SAB Biotherapeutics, Inc. (Nasdaq: SABS) provides an update on the SAB-142 trial, reporting completion of dosing the third cohort with no observation of serum sickness. The Phase 1 clinical trial aims to investigate safety, tolerability, pharmacokinetics, and immunogenicity of SAB-142, a human anti-thymocyte immunoglobulin for delaying the onset or progression of type 1 diabetes (T1D).
MIAMI BEACH, Fla., April ...

Trytosaveabit

04/16 05:22

Update

$SABバイオセラピューティクス(SABS.US)$ SAB Biotherapeutics: on April 12, Completed Dosing of Cohort 3 for Phase One Trials of SAB-142, Has Not Observed Any Instances of Serum Sicknesses

Mcsnacks H Tupack

01/08 08:28

Good week for Stocks

$ヘロン・セラピューティクス(HRTX.US)$ announced partnership today and broke resistance Thursday. FDA approval in 15 days.It gaps at 1.95. Will run as high as 5.50.
$リキディア・テクノロジーズ(LQDA.US)$ Also has FDA approval in 15 days. Has no resistance. Will make a 5 year high after it breaks 22.00.
$Trio Petroleum(TPET.US)$ Announced news on Thursday. The last time it released similar news it took it a couple of days before it got going. After .40 it will run to .62 for 100% profit.
$シャープス・ステクノロジー(STSS.US)$ Ran up i...

Moomoo AI

2023/11/20 20:41

Ellias' significant experience and expertise in T1D will greatly benefit SAB's Board of Directors, stated Samuel J. Reich, Executive Chairman of SAB. Acknowledging the company's promising position in T1D, Ellias expressed her enthusiasm for joining SAB's Board of Directors.

Press Release: SAB Biotherapeutics Appoints Katie Ellias to the Board of Directors

Moomoo AI

2023/10/24 19:43

Mr. King's experience will boost growth and shareholder value, says company. He anticipates a bright future for SAB with progress in type-1 diabetes trials and commercialization.